MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • All Meetings
    • 2026 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2018 International Congress

    Does motor laterality affect the development of dyskinesia in patients with Parkinson’s disease?

    S. Chung, H. Yoo, J. Oh, J. Kim, P. Lee, Y. Sohn (Seoul, Republic of Korea)

    Objective: To investigate the effects of motor laterality on the development of levodopa-induced dyskinesia (LID) in patients with de novo Parkinson’s disease (PD). Background: LID…
  • 2018 International Congress

    Acute efficacy and tolerability of the COMT inhibitor opicapone

    F. Gandor, D. Sykora, D. Gruber, G. Ebersbach (Beelitz-Heilstätten, Germany)

    Objective: Evaluation of the acute efficacy and tolerability of Opicapone. Background: Opicapone is a Catechol-O-Methyltransferase (COMT) inhibitor for the treatment of patients with idiopathic Parkinson’s…
  • 2018 International Congress

    L-Dopa responsiveness in early Parkinson’s disease: Results from the United Kingdom Tracking Parkinson’s study

    N. Malek, S. Kanavou, M. Lawton, K. Grosset, V. Pitz, N. Bajaj, R. Barker, D. Burn, T. Foltynie, J. Hardy, N. Wood, N. Williams, H. Morris, Y. Ben-Shlomo, D. Grosset (Ipswich, United Kingdom)

    Objective: We wanted to evaluate L-dopa responsiveness in a large cohort of patients with recently diagnosed Parkinson’s disease (PD) using an acute L-dopa challenge test.…
  • 2018 International Congress

    Efficacy of CVT-301 (levodopa inhalation powder) for treatment of OFF periods in Parkinson’s disease

    R. Pahwa, I. Abeynayake, M. Klingler, A. Sedkov, C. Kenney, C. Oh (Overland Park, KS, USA)

    Objective: Post-hoc analysis of subjects with Parkinson’s disease (PD) achieving > 30% reduction in UPDRS motor score (UPDRSIII) from pre- to post-dose over the first…
  • 2018 International Congress

    Perceived Psychosocial Impacts of a Therapeutic Yoga Intervention for Individuals with Parkinson’s Disease (PD)

    B. Hawkins, M. Van Puymbroeck, A. Walter, K. Woschkolup, E. Urrea-Mendoza, F. Revilla, A. Schmid (Clemson, SC, USA)

    Objective: This qualitative study sought to understand the psychosocial impacts of a therapeutic yoga intervention for individuals with PD originally designed to improve balance and…
  • 2018 International Congress

    Efficacy of combined treatment with acupunture and bee venom acupuncture for Parkinson’s disease: Double blind randomized controlled trial

    S.U. Park, H.M. Lee, S.Y. Cho, J.M. Park, C.N. Ko (Seoul, Republic of Korea)

    Objective: The aim of this study was to evaluate the efficacy of acupuncture and BVA for IPD through a sham-controlled trial. We also investigated whether…
  • 2018 International Congress

    Safety of sublingual apomorphine film (APL-130277) for the treatment of OFF episodes in patients with Parkinson’s disease: Results from a Phase 3 double-blind, placebo-controlled trial

    R. Pahwa, R. Hauser, M. Worden, P. Bhargava, G. Vakili, A. Agro, D. Blum, W. Olanow, B. Navia (Kansas City, KS, USA)

    Objective: To evaluate the safety of APL-130277 (APL) in the double-blind, placebo-controlled trial Titration Phase (TP) and Maintenance Phase (MP). Background: OFF episodes are a…
  • 2018 International Congress

    A phase Ib trial studying the safety and tolerability of IRL790 in patients with Parkinson’s disease and levodopa-induced dyskinesia

    P. Svenningsson, A. Johansson, D. Nyholm, P. Tsitsi, C. Sonesson, J. Tedroff (Stockholm, Sweden)

    Objective: The primary objective was to investigate the safety and tolerability of IRL790 in PD patients with LID in a randomized controlled trial. Background: IRL790…
  • 2018 International Congress

    Safety and Efficacy of Levodopa-Carbidopa Monotherapy in Patients with Advanced Parkinson’s Disease

    J. Boyd, C. Zadikoff, M. Siddiqui, J. Benesh, J. Zamudio, W. Robieson, P. Kukreja (Burlington, VT, USA)

    Objective: Evaluate efficacy/safety of levodopa-carbidopa intestinal gel (LCIG) daytime monotherapy (with/without nighttime oral carbidopa/levodopa) vs polytherapy (LCIG with >1 adjunctive therapy) in advanced Parkinson’s disease…
  • 2018 International Congress

    Individualization of levodopa treatment using a microtablet dispenser and ambulatory accelerometry

    D. Johansson, A. Ericsson, A. Johansson, A. Medvedev, D. Nyholm, F. Ohlsson, M. Senek, J. Spira, I. Thomas, J. Westin, F. Bergquist (Gothenburg, Sweden)

    Objective: This four-week open-label observational study describes the effect of introducing a microtablet dose dispenser and adjusting doses based on objective free-living motor symptom monitoring…
  • « Previous Page
  • 1
  • …
  • 1437
  • 1438
  • 1439
  • 1440
  • 1441
  • …
  • 1942
  • Next Page »

Related Sites

International Parkinson and Movement Disorder Society

The Society that manages the annual International Congress »

International Congress

The official website for the International Congress of Parkinson’s and Movement Disorders® »

  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley